{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:29:04Z","timestamp":1793813344525,"version":"4.6.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.annonc.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:33:57Z","timestamp":1790714037000},"page":"1459-1460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term benefit from immune checkpoint inhibition in squamous esophageal cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"V.E.","family":"Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-1817","authenticated-orcid":false,"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2026.09.001_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.001_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","article-title":"Epidemiology of esophageal squamous cell carcinoma","volume":"154","author":"Abnet","year":"2018","journal-title":"Gastroenterology"},{"issue":"7636","key":"10.1016\/j.annonc.2026.09.001_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.001_bib4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41588-021-00928-6","article-title":"Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence","volume":"53","author":"Moody","year":"2021","journal-title":"Nat Genet"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.001_bib5","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.001_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.annonc.2026.08.001","article-title":"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648","volume":"37","author":"Kato","year":"2026","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.001_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"10302","key":"10.1016\/j.annonc.2026.09.001_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study","volume":"10","author":"Metges","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.001_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"16 suppl","key":"10.1016\/j.annonc.2026.09.001_bib11","article-title":"Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): a multicenter, randomized, open-label, phase III study","volume":"44","author":"Lu","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2 suppl","key":"10.1016\/j.annonc.2026.09.001_bib12","article-title":"A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent\/metastatic esophageal squamous cell carcinoma","volume":"44","author":"Wang","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:31:45Z","timestamp":1793809905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0923753426066329"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term benefit from immune checkpoint inhibition in squamous esophageal cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.08.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}